Today: 29 April 2026
P&G stock price today: Procter & Gamble edges higher as shutdown clouds key data
2 February 2026
2 mins read

P&G stock price today: Procter & Gamble edges higher as shutdown clouds key data

New York, Feb 2, 2026, 14:18 EST — Regular session

  • P&G shares climbed in afternoon trading, following gains across the consumer-staples sector
  • The January jobs report was postponed due to a partial U.S. government shutdown, injecting uncertainty into the week’s data schedule
  • Investors are focused on upcoming funding decisions in Washington and P&G’s dividend payout scheduled for Feb. 17

Procter & Gamble shares edged up roughly 0.7% to $152.82 in afternoon trading Monday, fluctuating between $151.37 and $153.21. The Consumer Staples Select Sector SPDR Fund climbed about 1%. Colgate-Palmolive and Church & Dwight saw gains, while Kimberly-Clark dipped. Unilever’s stock remained mostly flat.

This move is significant because major consumer staples stocks have turned into a safe haven whenever macro headlines get tangled. Traders face a week loaded with earnings and economic data, yet one crucial indicator has abruptly vanished.

Procter & Gamble’s stock often serves as a quick test of its pricing power. When investors believe consumers will continue paying up for branded essentials, they’re usually willing to accept slower volume growth and view the shares as a steadying force.

The broader market recovered from early losses sparked by a steep fall in precious metals, as tech and memory stocks pushed major indexes up, Reuters reported. “We’re heading into a new week with plenty of catalysts in front of us,” said Art Hogan of B. Riley Wealth. Reuters

New data stirred the mix. The Institute for Supply Management reported its Purchasing Managers’ Index (PMI) climbed to 52.6 in January, marking the first expansion in 12 months, boosted by a surge in new orders. Susan Spence noted, “some buying appears to be to get ahead of expected price increases due to ongoing tariff issues.” Reuters

Then came a curveball. The U.S. Bureau of Labor Statistics announced the January employment report won’t drop on Friday due to the partial government shutdown that started Saturday. “The release will be rescheduled upon the resumption of government funding,” said Emily Liddel. House lawmakers are expected to vote on funding by Tuesday, Reuters reports. Reuters

The company’s last major trigger was its Jan. 22 earnings report. Procter & Gamble posted revenue just below forecasts as U.S. consumer spending cooled, though core earnings per share — which exclude certain one-off items — surpassed estimates. The firm held firm on its full-year sales and core profit guidance. “We need to get the U.S. growing,” Andre Schulten told analysts. Reuters

Dividend investors eye a key date coming up soon. Procter & Gamble’s most recent quarterly dividend stands at $1.0568 per share, scheduled for payment on Feb. 17. The stock went ex-dividend on Jan. 23, according to the company’s dividend history.

That “defensive” trade can flip just as fast. If risk appetite holds, funds might shift out of staples in a hurry. P&G faces the challenge of boosting volumes without relying too much on price hikes, particularly since tariffs and input costs remain a wildcard for margins.

Traders now eye Tuesday’s House vote on restoring government funding and look for any update on the postponed jobs report’s new date. For P&G investors, the closest company event is the Feb. 17 dividend payout.

Stock Market Today

  • Mesoblast Shares Falter Amid Growing Uncertainty Over Growth Prospects
    April 28, 2026, 10:58 PM EDT. Mesoblast (ASX:MSB) shares closed at A$2.15, down 6.5% over the past week despite a 0.5% gain in the last day. The biopharma firm shows mixed signals: positive 1- and 3-year shareholder returns contrast with weaker short-term performance. Analysts highlight Mesoblast as 43.9% undervalued with a fair value target of A$3.83, driven by heart failure drug rexlemestrocel L, pending potential U.S. accelerated FDA approval. However, risks loom from slow Ryoncil sales and trial delays. Valuation models conflict; discounted cash flow suggests undervaluation at A$3.05, but a high price-to-sales ratio of 30.5x versus industry norms raises questions if the market overpays for growth or if assumptions are overstretched. Investors remain cautious amid uncertain future earnings and regulatory hurdles.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Cisco stock pops to a fresh 52-week high — here’s what Wall Street is watching next
Previous Story

Cisco stock pops to a fresh 52-week high — here’s what Wall Street is watching next

Nebius (NBIS) stock rebounds after a wild session as Feb. 12 results loom
Next Story

Nebius (NBIS) stock rebounds after a wild session as Feb. 12 results loom

Go toTop